Autopsy report · NCT01852110

Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012)

“Stage 1 interim analysis of efficacy met the criteria for early trial termination (futility). The trial was terminated at Stage 1; did not proceed to Stage 2.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months before it started.
• Ran for about 2 years 6 months before it stopped.
• 240 participants enrolled.
• Results were posted on the registry 1 year 10 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Merck Sharp & Dohme LLC

Sponsor type

Industry

Conditions

Alzheimer's Disease

Interventions

MK-7622; Placebo; AChEI

Participants

240

Trials that died the same way

• Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)
  “The study was terminated based on the results of a planned interim analysis that showed futility of efficacy.” (82% match in meaning)
• Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma
  “The trial was terminated early based on an interim review by the Data and Safety Monitoring Committee for positive efficacy outcome and no safety concerns.” (77% match in meaning)
• An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
  “An independent assessment concluded the trial was not likely to meet the primary endpoint upon completion and therefore, trial stopped for futility” (76% match in meaning)
• Removal Versus Retention of Cerclage in Preterm Premature Rupture of Membranes (PPROM)
  “This trial was terminated following a futility analysis confirming futility of continuing the study” (76% match in meaning)
• The Impact of IVIG Treatment on Critical Illness Polyneuropathy and/or Myopathy in Patients With MOF and SIRS/Sepsis
  “The trial was terminated early due to futility in reaching the primary endpoint.” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.